1,940 Shares in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Purchased by R Squared Ltd

R Squared Ltd purchased a new position in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund purchased 1,940 shares of the company’s stock, valued at approximately $26,000.

Several other institutional investors have also modified their holdings of SNDX. Sei Investments Co. lifted its stake in shares of Syndax Pharmaceuticals by 13.5% in the second quarter. Sei Investments Co. now owns 45,928 shares of the company’s stock worth $943,000 after acquiring an additional 5,465 shares in the last quarter. The Manufacturers Life Insurance Company lifted its stake in shares of Syndax Pharmaceuticals by 16.1% in the second quarter. The Manufacturers Life Insurance Company now owns 48,668 shares of the company’s stock worth $999,000 after acquiring an additional 6,755 shares in the last quarter. Creative Planning lifted its stake in shares of Syndax Pharmaceuticals by 27.4% in the second quarter. Creative Planning now owns 18,428 shares of the company’s stock worth $378,000 after acquiring an additional 3,962 shares in the last quarter. Northwestern Mutual Wealth Management Co. acquired a new position in shares of Syndax Pharmaceuticals in the second quarter worth about $27,000. Finally, Inspire Investing LLC lifted its stake in shares of Syndax Pharmaceuticals by 23.2% in the third quarter. Inspire Investing LLC now owns 21,308 shares of the company’s stock worth $410,000 after acquiring an additional 4,018 shares in the last quarter.

Analysts Set New Price Targets

Several analysts have issued reports on the company. JPMorgan Chase & Co. upped their price objective on Syndax Pharmaceuticals from $33.00 to $38.00 and gave the company an “overweight” rating in a research note on Thursday, November 21st. The Goldman Sachs Group upped their price objective on Syndax Pharmaceuticals from $30.00 to $33.00 and gave the company a “buy” rating in a research note on Thursday, November 7th. UBS Group assumed coverage on Syndax Pharmaceuticals in a research note on Thursday, October 24th. They set a “buy” rating and a $37.00 price objective on the stock. Scotiabank cut their price objective on Syndax Pharmaceuticals from $18.00 to $16.00 and set a “sector perform” rating on the stock in a research note on Wednesday, January 8th. Finally, StockNews.com cut Syndax Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Saturday, November 23rd. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and nine have given a buy rating to the stock. Based on data from MarketBeat, Syndax Pharmaceuticals has an average rating of “Moderate Buy” and a consensus target price of $36.20.

Syndax Pharmaceuticals Price Performance

Shares of SNDX stock opened at $14.41 on Wednesday. Syndax Pharmaceuticals, Inc. has a 12-month low of $12.06 and a 12-month high of $25.34. The firm has a market capitalization of $1.23 billion, a price-to-earnings ratio of -3.97 and a beta of 0.90. The business has a 50 day simple moving average of $14.14 and a 200 day simple moving average of $17.57.

Syndax Pharmaceuticals (NASDAQ:SNDX) last issued its quarterly earnings data on Tuesday, November 5th. The company reported ($0.98) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.13) by $0.15. The business had revenue of $12.50 million during the quarter, compared to the consensus estimate of $9.16 million. During the same period last year, the company earned ($0.73) earnings per share. On average, equities analysts anticipate that Syndax Pharmaceuticals, Inc. will post -3.71 EPS for the current fiscal year.

Syndax Pharmaceuticals Company Profile

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).